ArticleJournal of medicinal chemistry2021
Macrocyclic Peptides that Selectively Inhibit the
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Fred Goldberg machines in the pathogenesis of Mycobacterium tuberculosis.The Journal of biological chemistry · 2026Review
- Inhibitors of the 20S proteasome β5 subunit as potent and selective agents againstAntimicrobial agents and chemotherapy · 2025Article
- Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies.Journal of medicinal chemistry · 2025Review
- A membrane permeability database for nonpeptidic macrocycles.Scientific data · 2025Article
- High throughput screening assay for the identification of ATF4 and TFEB activating compounds.Autophagy reports · 2025Article
- Review
- Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.Pharmaceutics · 2023Review
- Comprehensive essentiality analysis of themBio · 2023Article
- Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.Antimicrobial agents and chemotherapy · 2022Article
- Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.Journal of medicinal chemistry · 2022Article
- Structural basis of prokaryotic ubiquitin-like protein engagement and translocation by the mycobacterial Mpa-proteasome complex.Nature communications · 2022Article
- Microbial proteasomes as drug targets.PLoS pathogens · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 1 country.
Hao ZhangDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.ORCID 0000-0002-1187-5844
Hao-Chi HsuDepartment of Structural Biology, Van Andel Institute, 333 Bostwick Avenue NE, Grand Rapids, Michigan 49503, United States.
Shoshanna C KahneDepartment of Microbiology, New York University School of Medicine, 430 E. 29th Street, New York, New York 10016, United States.
Ryoma HaraTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Wenhu ZhanDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.ORCID 0000-0002-7095-7081
Xiuju JiangDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.
Kristin Burns-HuangDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.
Tierra OuelletteDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.
Toshihiro ImaedaTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Rei OkamotoTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Masanori KawasakiTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Mayako MichinoTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Tzu-Tshin WongTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Akinori ToitaTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Takafumi YukawaTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Francesca MoracaSchrödinger, Inc., New York, New York 10036, United States.ORCID 0000-0003-0248-9834
Jeremie VendomeSchrödinger, Inc., New York, New York 10036, United States.
Priya SahaDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.
Kenjiro SatoTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Kazuyoshi AsoTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
John GinnTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Peter T MeinkeTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Michael FoleyTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10065, United States.
Carl F NathanDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.
K Heran DarwinDepartment of Microbiology, New York University School of Medicine, 430 E. 29th Street, New York, New York 10016, United States.
Huilin LiDepartment of Structural Biology, Van Andel Institute, 333 Bostwick Avenue NE, Grand Rapids, Michigan 49503, United States.ORCID 0000-0001-8085-8928
Gang LinDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States.ORCID 0000-0003-4797-7073
Tri-Institutional Therapeutics Discovery Institute · USCornell University · USNew York University · USSchrodinger (United States) · USVan Andel Institute · US
Funding
INFECTIOUS DISEASES &BASIC MICROBIOLOGICAL MECHANISMST32AI007180 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 1985 to 2022
$8.9MPROTEASOME-DEPENDENT DEGRADATION IN MYCOBACTERIUM TUBERCULOSISR01AI088075 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Katerina Heran Darwin · 2011 to 2026
$6.5MStructure Biology of Mycobacterium Tuberculosis Pup-Proteasome PathwayR01AI070285 · NIAID · VAN ANDEL RESEARCH INSTITUTE · PI LI, HUILIN · 2007 to 2022
$6.5MSelective Plasmodium proteasome inhibitors as novel multi-stage antimalarialsR01AI143714 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gang Lin · 2019 to 2026
$6.1MMacrocyclic proteasome inhibitors for treatment of tuberculosisR21AI144552 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIN, GANG · 2020 to 2021
$466kNIAID NIH HHS R01 AI070285NIAID NIH HHS R01 AI088075NIAID NIH HHS R01 AI143714NIAID NIH HHS R21 AI144552NIAID NIH HHS T32 AI007180
Abstract
Treatment of tuberculosis (TB) currently takes at least 6 months. Latent
Indexed as
Anti-Bacterial AgentsDrug DesignHumansMycobacterium tuberculosisPeptides, CyclicProteasome Endopeptidase ComplexProteasome InhibitorsStructure-Activity RelationshipAnti-Bacterial AgentsPeptides, CyclicProteasome Endopeptidase ComplexProteasome Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.